RxDoctor Payments Data

Alexander Tatem, MD

Urology · Carmel, INNPI 1114364064

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $259,604 of the $418,070 with a category attached, or 62.1%. Boston Scientific accounts for 62.0% of it on its own, with 43 other manufacturers making up the rest. Among urology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$418,070in general payments, 2019–2025

Across 1,022 payments — averaging $409.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$259K
  • Endo Pharmaceuticals Inc.$78K
  • Endo USA, Inc.$26K
  • Central Indiana URS Consumables, LLC$22K
  • Coloplast$21K
  • Marius Pharmaceuticals, Inc$8K
  • plus $4K from 38 others
$7,775in research payments, 2019–2025

Across 2 payments — averaging $3887.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Endo USA, Inc.$8K
$15,600in ownership & investment interests, 2019–2025

Across 2 payments — averaging $7800.00 each. An ownership or investment interest held by the physician or an immediate family member.

  • Central Indiana URS Consumables, LLC$16K

What the payments were for

  • Consulting fees$60,51314%
  • Speaking & faculty fees$259,60462%
  • Travel & lodging$36,8389%
  • Food & beverage$28,6697%
  • Education$10,3762%
  • Other$22,0715%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$418,070 in reported general payments places this provider in the 95th percentile of 272 urology providers in Indiana.

See all urology providers in Indiana

Medicare billing

Part B allowed, 2024
$250,088
Medicare patients
309
Services billed
2,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib179$5,136
Cabergoline19$1,861
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim174$807
Testosterone Cypionate13$608
Gabapentin196$441
Anastrozole36$268
Ciprofloxacin Hcl19$125
Doxycycline Hyclate19$120
Sildenafil Citrate11$119
Tamsulosin Hcl14$101
Clindamycin Hcl12$49

Paid to pharmacies, not to this prescriber.

Other urology in Carmel

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →